SABATTINI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 7.927
AS - Asia 7.264
EU - Europa 5.106
AF - Africa 455
SA - Sud America 391
OC - Oceania 12
Totale 21.155
Nazione #
US - Stati Uniti d'America 7.803
VN - Vietnam 2.026
SG - Singapore 1.919
CN - Cina 1.869
GB - Regno Unito 1.238
IT - Italia 722
SE - Svezia 692
DE - Germania 683
HK - Hong Kong 454
FR - Francia 358
IN - India 338
UA - Ucraina 309
BR - Brasile 268
RU - Federazione Russa 267
IE - Irlanda 191
KR - Corea 152
NL - Olanda 140
ZA - Sudafrica 131
JP - Giappone 121
FI - Finlandia 113
CI - Costa d'Avorio 110
TG - Togo 92
EE - Estonia 67
CA - Canada 66
CH - Svizzera 66
BD - Bangladesh 65
AR - Argentina 47
JO - Giordania 47
BG - Bulgaria 41
NG - Nigeria 39
BE - Belgio 38
PH - Filippine 37
MX - Messico 35
ID - Indonesia 34
SC - Seychelles 33
TH - Thailandia 32
IR - Iran 26
LU - Lussemburgo 25
TR - Turchia 23
AT - Austria 22
EC - Ecuador 22
PL - Polonia 22
TW - Taiwan 22
ES - Italia 20
HR - Croazia 20
IQ - Iraq 17
GR - Grecia 16
CO - Colombia 15
SA - Arabia Saudita 15
PK - Pakistan 14
LT - Lituania 12
RO - Romania 12
UZ - Uzbekistan 11
AU - Australia 10
CL - Cile 10
EG - Egitto 9
LB - Libano 8
PE - Perù 8
PY - Paraguay 8
KE - Kenya 7
DZ - Algeria 6
JM - Giamaica 6
DK - Danimarca 5
MA - Marocco 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
GH - Ghana 4
KG - Kirghizistan 4
PA - Panama 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
AZ - Azerbaigian 3
ET - Etiopia 3
GT - Guatemala 3
IL - Israele 3
KH - Cambogia 3
LV - Lettonia 3
MY - Malesia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GY - Guiana 2
HN - Honduras 2
HU - Ungheria 2
MD - Moldavia 2
NP - Nepal 2
OM - Oman 2
PR - Porto Rico 2
RS - Serbia 2
UG - Uganda 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 21.139
Città #
Singapore 1.334
Southend 1.042
Ashburn 852
Fairfield 764
Chandler 476
San Jose 472
Hong Kong 425
Dong Ket 394
Hanoi 362
Ho Chi Minh City 357
Hefei 340
Houston 337
Woodbridge 334
Seattle 331
Wilmington 327
Cambridge 284
Ann Arbor 273
Princeton 270
Beijing 237
Santa Clara 214
Dublin 190
Jacksonville 179
Boardman 177
Lauterbourg 136
Seoul 134
New York 123
Los Angeles 122
Nanjing 121
Abidjan 110
Tokyo 106
Westminster 106
Bologna 97
Lomé 92
Padova 89
Helsinki 84
Bremen 78
Berlin 77
Dallas 70
Buffalo 69
Milan 69
Council Bluffs 64
London 64
Haiphong 63
Jinan 61
Da Nang 60
Bern 56
Saint Petersburg 51
Frankfurt am Main 50
Shenyang 48
Amman 47
San Diego 45
Hebei 44
Mülheim 44
São Paulo 43
Nanchang 42
Munich 40
Redondo Beach 40
Sofia 40
Changsha 38
Tianjin 38
Brussels 37
Chicago 37
Shanghai 37
Guangzhou 36
Abeokuta 35
Bengaluru 32
Johannesburg 31
Hyderabad 29
Hangzhou 28
Phoenix 27
Rome 27
Zhengzhou 27
Medford 26
Redwood City 26
Turin 25
Redmond 24
Jiaxing 23
Hải Dương 21
Orem 21
Des Moines 20
Lappeenranta 20
San Venanzo 20
The Dalles 20
Toronto 20
Falkenstein 19
Olalla 19
Taizhou 19
Yubileyny 19
Haikou 18
Norwalk 18
Florence 17
Thái Nguyên 17
Brooklyn 16
Can Tho 16
Dearborn 16
Mahé 16
Montreal 16
Warsaw 16
Chennai 15
Quận Bình Thạnh 15
Totale 13.553
Nome #
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 290
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 287
Biology and treatment of follicular lymphoma. 282
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 277
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 273
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 269
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 258
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 252
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 243
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 239
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 228
Primary cutaneous large B-cell lymphoma, leg type, localized on the dorsum 226
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 213
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
A case report of IgG4-related disease: an insidious path to the diagnosis through kidney, heart and brain 209
Aberrant expression of CD10 and BCL6 in mantle cell lymphoma 208
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 208
Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment. 205
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 201
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 199
CD30 expression in peripheral T-cell lymphomas 195
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 194
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 192
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 191
Histopathology of B-cell chronic lymphocytic leukemia. 190
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 186
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 186
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 183
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 182
Two Different Extranodal Lymphomas in an HIV+ Patient: A Case Report and Review of the Literature 181
Anaplastic Large Cell Lymphoma: a critical reappraisal 180
The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma 180
First Italian birth after cryopreserved ovarian tissue transplantation in a patient affected by non-Hodgkin's lymphoma 180
BCL10 down-regulation in peripheral T-cell lymphomas. 179
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 179
Pathobiology of hodgkin lymphoma. 179
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 178
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 178
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman’s disease: an unusual occurrence 178
Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact 174
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 173
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 173
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 172
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 171
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 171
Unusual inflammatory and hyperkeratotic halo naevus in children. 171
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 170
Pathobiology of anaplastic large cell lymphoma. 170
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 166
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 165
High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. 162
Granulomatous tattoo reaction in a nivolumab-treated patient 162
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (Modern Pathology, (2020), 33, 2, (179-187), 10.1038/s41379-019-0279-8) 161
The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis 160
Pathobiology of ALK-negative anaplastic large cell lymphoma. 160
Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders (SMPLPD), demographical, clinical, therapeutic and prognostic aspects: a retrospective monocentric analysis 159
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. 159
Newly-discovered neural features expand the pathobiological knowledge of blastic plasmacytoid dendritic cell neoplasm 158
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 157
BCL10 expression in peripheral T-cell lymphoma not otherwise specified. 156
Simple diagnostic assay for hairy cell leukemia by cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 154
Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas 154
Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin’s disease. 153
WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. 153
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 153
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 153
Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment 152
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. 150
Primary cutaneous lymphomas: a reprisal 148
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 147
The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET 146
Prognostic markers in peripheral T-cell lymphoma. 146
Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. 146
Use of IGK gene rearrangement analysis for clonality assesment of lymphoid malignancies. A single center experience. 144
Molecular Diagnosis of Peripheral T-Cell Lymphoma/NOS From Formalin Fixed Paraffin Embedded Tissues. 144
Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in 5 cases. 142
Idiopathic follicular mucinosis: Can dermoscopy be helpful? 142
Brownish asymptomatic lesions on the arms and legs 142
Multiple intra-axial lesions in a 57-year-old male with a history of B-cell chronic lymphocytic leukemia 142
Genetic and phenotypic attributes of splenic marginal zone lymphoma 141
Pathobiology of acute lymphoblastic leukemia. 141
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 139
Variable activation of canonical and alternative NF-Kappa B pathway in peripheral T-Cell Lymphoma not otherwise specified. 138
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity—reply 138
Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab 138
Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges 137
Pityriasis lichenoides getriggert durch eine Masern‐Mumps‐Röteln‐Impfung 136
IN CHRONIC LYMPHOCYTIC LEUKEMIA THE AMOUNT OF PROLIFERATION CENTERS IN TISSUE-BIOPSIES CORRELATES WITH UNFAVORABLE CYTOGENETIC ABNORMALITIES 134
The role of peritumoral CD8 + /TIA1 + lymphocytes in hepatocellular carcinoma aggressiveness and recurrence after surgical resection 133
Correction: Bertuzzi et al. Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact. Cancers 2024, 16, 4210 133
Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktärem Sézary-Syndrom 133
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 132
The Medium Obtained from the Culture of Hodgkin Lymphoma Cells Affects the Biophysical Characteristics of a Fibroblast Cell Model 130
Safety of cryopreserved ovarian tissue autotransplantation in leukaemia patients 130
Bone marrow in Hodgkin lymphoma and mimickers. 129
Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients 129
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 129
Peripheral T-cell lymphoma. 128
Use of IGK gene rearrangement analysis for clonality assessment of lymphoid malignancies: a single center experience. 128
Totale 17.408
Categoria #
all - tutte 58.680
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.680


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021742 0 0 0 0 0 0 0 0 0 0 0 742
2021/20222.176 178 93 135 179 239 106 43 151 82 172 468 330
2022/20232.483 295 390 145 311 177 186 72 125 409 65 188 120
2023/2024713 37 120 62 56 64 159 45 52 23 52 13 30
2024/20252.918 136 447 283 209 391 142 243 96 44 197 161 569
2025/20267.166 624 675 622 612 809 367 706 262 1.404 549 265 271
Totale 21.532